Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics

CNS Drugs

Volumn 24, Issue 2, 2010, Pages 99-117

  Froehlich, Tanya E ^a   McGough, James J ^b,c   Stein, Mark A ^d  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE; NORADRENALIN TRANSPORTER; OROS; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ALGORITHM; ATTENTION DEFICIT DISORDER; DRUG METABOLISM; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE INTERACTION; HEREDITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SHORT COURSE THERAPY;

AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CATECHOL O-METHYLTRANSFERASE; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; METABOLIC DETOXICATION, DRUG; METHYLPHENIDATE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROPYLAMINES; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DOPAMINE D4; RECEPTORS, DOPAMINE D5; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

EID: 74949113916     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11530290-000000000-00000     Document Type: Review

References (107)

1. Prince JB. Pharmacotherapy of attention-deficit hyper-activity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments. Child Adolesc Psychiatr Clin N Am 2006 Jan; 15 (1): 13-50
2. Faraone SV, Biederman J, Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. Med Gen Med 2006; 8 (4): 4
3. Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry 2004 May; 43 (5): 559-567
4. National Institute of Mental Health. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004 Apr;113 (4):754-761.
5. Katusic SK, Barbaresi WJ, Colligan RC, et al. Psychostimu-lant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 2005 Oct; 15 (5): 764-776
6. Barbaresi WJ, Katusic SK, Colligan RC, et al. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Ped 2007 Aug; 28 (4): 274-286
7. Lowe N, Barry E, Gill M, et al. An overview of the phar-macogenetics and molecular genetics of ADHD. Curr Pharmacogen 2006; 4: 231-243
8. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998 Nov 15; 44 (10): 951-958
9. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genet-ics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005 Jun 1; 57 (11): 1313-1323
10. Weber WW. Pharmacogenetics. New York: Oxford Press, 1997
11. Phillips KA, Veenstra DL, Sadee W. Implications of the genetics revolution for health services research: pharma-cogenomics and improvements in drug therapy. Health Serv Res 2000 Dec; 35 (5 Pt 3): 128-140
12. Aitchison KJ, Gill M. Pharmacogenetics in the postgenomic era. In: Plomin R, Devries J, Craig I, et al., editors. Behavioral genetics in the postgenomic era. Washington, DC: American Psychological Association, 2003
13. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999 Oct 15; 286 (5439): 487-491
14. Staddon S, Arranz MJ, Mancama D, et al. Clinical appli-cations of pharmacogenetics in psychiatry. Psycho-pharmacology 2002 Jun; 162 (1): 18-23
15. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav Brain Res 1998 Jul; 94 (1): 127-152
16. Eisenberg J, Mei-Tal G, Steinberg A, et al. Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am J Med Genet 1999 Oct 15; 88 (5): 497-502
17. Qian Q, Wang Y, Zhou R, et al. Family-based and case-control association studies of catechol-O-methyltransfer-ase in attention deficit hyperactivity disorder suggest genetic sexual dimorphism. Am J Med Genet B Neuro-psychiatr Genet 2003 Apr 1; 118 (1): 103-109
18. Roman T, Schmitz M, Polanczyk GV, et al. Is the alpha-2A adrenergic receptor gene (ADRA2A) associated with attention-deficit/hyperactivity disorder? Am J Med Genet B Neuropsychiatr Genet 2003 Jul 1; 120 (1): 116-120
19. Roman T, Polanczyk GV, Zeni C, et al. Further evidence of the involvement of alpha-2A-adrenergic receptor gene (ADRA2A) in inattentive dimensional scores of atten-tion-deficit/hyperactivity disorder. Mol Psychiatry 2006 Jan; 11 (1): 8-10
20. Schmitz M, Denardin D, Silva TL, et al. Association between alpha-2a-adrenergic receptor gene and ADHD inattentive type. Biol Psychiatry 2006 Nov 15; 60 (10): 1028-1033
21. Bobb AJ, Addington AM, Sidransky E, et al. Support for association between ADHD and two candidate genes: NET1 and DRD 1. Am J Med Genet B Neuropsychiatr Genet 2005 Apr 5; 134 (1): 67-72
22. Kim CH, Hahn MK, Joung Y, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci USA 2006 Dec 12; 103 (50): 19164-19169
23. McGough JJ. Attention-deficit/hyperactivity disorder pharmacogenomics. Biol Psychiatry 2005 Jun 1; 57 (11): 1367-1373
24. Polanczyk G, Zeni C, Genro JP, et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007 Feb; 64 (2): 218-224
25. da Silva TL, Pianca TG, Roman T, et al. Adrenergic alpha2A receptor gene and response to methylphenidate in attention-deficit/hyperactivity disorder-predominantly inattentive type. J Neural Transm 2008; 115 (2): 341-345
26. Kereszturi E, Tarnok Z, Bognar E, et al. Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet B Neuropsychiatr Genet 2008 Jan 23; 147B (8): 1431-1435
27. Stein MA, Waldman ID, Sarampote CS, et al. Dopamine transporter genotype and methylphenidate dose response in children with ADHD. Neuropsychopharmacology 2005 Jul; 30 (7): 1374-1382
28. McGough J, McCracken J, Swanson J, et al. Pharmaco-genetics of methylphenidate response in preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006 Nov; 45 (11): 1314-1322
29. Joober R, Grizenko N, Sengupta S, et al. Dopamine transporter 3-UTR VNTR genotype and ADHD: a pharmaco-behavioural genetic study with methylpheni-date. Neuropsychopharmacology 2007 Jun; 32 (6): 1370-1376
30. Winsberg BG, Comings DE. Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J Am Acad Child Adolesc Psychiatry 1999 Dec; 38 (12): 1474-1477
31. Roman T, Szobot C, Martins S, et al. Dopamine transporter gene and response to methylphenidate in attention-deficit/hyperactivity disorder. Pharmacogenetics 2002 Aug; 12 (6): 497-499
32. Kirley A, Lowe N, Hawi Z, et al. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuro-psychiatr Genet 2003 Aug 15; 121 (1): 50-54
33. Cheon KA, Ryu YH, Kim JW, et al. The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsycho-pharmacol 2005 Jan; 15 (1): 95-101
34. Langley K, Turic D, Peirce TR, et al. No support for as-sociation between the dopamine transporter (DAT1) gene and ADHD. Am J Med Genet B Neuropsychiatr Genet 2005 Nov 5; 139 (1): 7-10
35. van der Meulen EM, Bakker SC, Pauls DL, et al. High sibling correlation on methylphenidate response but no association with DAT1-10R homozygosity in Dutch sib-pairs with ADHD. J Child Psychol Psychiatry 2005 Oct; 46 (10): 1074-1080
36. Bellgrove MA, Barry E, Johnson KA, et al. Spatial atten-tional bias as a marker of genetic risk, symptom severity, and stimulant response in ADHD. Neuropsycho-pharmacology 2008 Nov 28; 33: 2536-2545
37. Zeni CP, Guimaraes AP, Polanczyk GV, et al. No nificant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention-deficit/ hyperactivity disorder. Am J Med Genet B Neuro-psychiatr Genet 2007 Apr 5; 144 (3): 391-394
38. Purper-Ouakil D, Wohl M, Orejarena S, et al. Pharmaco-genetics of methylphenidate response in attention deficit/ hyperactivity disorder: association with the dopamine transporter gene (SLC6A3). Am J Med Genet B Neuro-psychiatr Genet 2008 Jun 18; 147B (8): 1425-1430
39. Tharoor H, Lobos EA, Todd RD, et al. Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am J Med Genet B Neuropsychiatr Genet 2008 Jun 5; 147B (4): 527-530
40. Tahir E, Yazgan Y, Cirakoglu B, et al. Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry 2000 Jul; 5 (4): 396-404
41. Seeger G, Schloss P, Schmidt MH. Marker gene poly-morphisms in hyperkinetic disorder: predictors of clinical response to treatment with methylphenidate? Neurosci Lett 2001 Nov 2; 313 (1-2): 45-48
42. Hamarman S, Fossella J, Ulger C, et al. Dopamine receptor 4 (DRD4) 7-repeat allele predicts methylphenidate dose response in children with attention deficit hyperactivity disorder: a pharmacogenetic study. J Child Adolesc Psychopharmacol 2004; 14 (4): 564-574
43. Cheon KA, Kim BN, Cho SC. Association of 4-repeat allele of the dopamine D4 receptor gene exon III polymorphism and response to methylphenidate treatment in Korean ADHD children. Neuropsychopharmacology 2007 Jun; 32 (6): 1377-1383
44. Yang L, Wang YF, Li J, et al. Association of norepine-phrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 2004 Sep; 43 (9): 1154-1158
45. Mick E, Biederman J, Spencer T, et al. Absence of associa-tion with DAT1 polymorphism and response to methyl-phenidate in a sample of adults with ADHD. Am J Med Genet B Neuropsychiatr Genet 2006 Dec 5; 141 (8): 890-894
46. Kooij JS, Boonstra AM, Vermeulen SH, et al. Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am J Med Genet B Neuropsychiatr Genet 2008 Mar 5; 147B (2): 201-208
47. Polanczyk G, Faraone SV, Bau CH, et al. The impact of individual and methodological factors in the variability of response to methylphenidate in ADHD pharmacogenetic studies from four different continents. Am J Med Genet B Neuropsychiatr Genet 2008 Dec 5; 147B (8): 1419-1424
48. Jorgensen A, Alfirevic A. Pharmacogenetics and pharma-cogenomics: adverse drug reactions. Pharmacogenomics 2008 Oct; 9 (10): 1397-1401
49. Wadelius M, Pirmohamed M. Pharmacogenetics of war-farin: current status and future challenges. Pharmacogen J 2007 Apr; 7 (2): 99-111
50. Volkow ND, Fowler JS, Wang G, et al. Mechanism of ac-tion of methylphenidate: insights from PET imaging studies. J Atten Disord 2002; 6 Suppl. 1: S31-43
51. Melega WP, Williams AE, Schmitz DA, et al. Pharmaco-kinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal. J Pharmacol Exper Ther 1995 Jul; 274 (1): 90-96
52. Cook Jr EH, Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 1995 Apr; 56 (4): 993-998
53. VanNess SH, Owens MJ, Kilts CD. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet 2005; 6: 55
54. Brookes K, Xu X, Chen W, et al. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 2006 Oct; 11 (10): 934-953
55. Asherson P, Brookes K, Franke B, et al. Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD. Am J Psychiatry 2007 Apr; 164 (4): 674-677
56. Brookes KJ, Mill J, Guindalini C, et al. A common hap-lotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry 2006 Jan; 63 (1): 74-81
57. Lott DC, Kim SJ, Cook Jr EH, et al. Dopamine transporter gene associated with diminished subjective response to amphetamine. Neuropsychopharmacology 2005 Mar; 30 (3): 602-609
58. Heckers S, Konradi C. Synaptic function and biochemical neuroanatomy. In: Martin A, Scahill L, Charney DS, et al., editors. Pediatric psychopharmacology: principles and practice. New York: Oxford University Press, 2003: 20-32
59. Asghari V, Sanyal S, Buchwaldt S, et al. Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 1995 Sep; 65 (3): 1157-1165
60. Van Tol HH, Wu CM, Guan HC, et al. Multiple dopamine D4 receptor variants in the human population. Nature 1992 Jul 9; 358 (6382): 149-152
61. Sallee FR, Newcorn J, Allen AJ, et al. Pharmacogenetics of atomoxetine: relevance of DRD 4. Scientific proceedings of the 51st Annual Meeting of the American Academy of Child and Adolescent Psychiatry; 2004 Oct 21; Washington, DC: 28
62. Nestler EJ, Hyman SE, Malenka RC. Molecular neuro-pharmacology: a foundation for clinical neuroscience. New York: The McGraw-Hill Companies, Inc., 2001
63. Arnsten AF, Dudley AG. Methylphenidate improves pre-frontal cortical cognitive function through alpha2 adre-noceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 2005 Apr 22; 1 (1): 2
64. Andrews GD, Lavin A. Methylphenidate increases cortical excitability via activation of alpha-2 noradrenergic receptors. Neuropsychopharmacology 2006 Mar; 31 (3): 594-601
65. Lario S, Calls J, Cases A, et al. MspI identifies a biallelic polymorphism in the promoter region of the alpha 2A-adrenergic receptor gene. Clin Genet 1997 Feb; 51 (2): 129-130
66. Deupree JD, Smith SD, Kratochvil CJ, et al. Possible in-volvement of alpha-2A adrenergic receptors in attention deficit hyperactivity disorder: radioligand binding and polymorphism studies. Am J Med Genet B Neuro-psychiatr Genet 2006 Dec 5; 141B (8): 877-884
67. Lachman HM, Papolos DF, Saito T, et al. Human catechol-O- methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996 Jun; 6 (3): 243-250
68. Cheuk DK, Wong V. Meta-analysis of association between a catechol-O-methyltransferase gene polymorphism and attention deficit hyperactivity disorder. Behav Genet 2006 Sep; 36 (5): 651-659 (Pubitemid 44188080)
69. Mattay VS, Goldberg TE, Fera F, et al. Catechol-O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003 May 13; 100 (10): 6186-6191
70. Holmes A, Hollon TR, Gleason TC, et al. Behavioral characterization of dopamine D5 receptor null mutant mice. Behav Neurosci 2001 Oct; 115 (5): 1129-1144
71. Lowe N, Kirley A, Hawi Z, et al. Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. Am J Hum Genet 2004 Feb; 74 (2): 348-356
72. Maher BS, Marazita ML, Ferrell RE, et al. Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. Psychiatr Genet 2002 Dec; 12 (4): 207-215
73. Li D, Sham PC, Owen MJ, et al. Meta-analysis shows sig-nificant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 2006 Jul 15; 15 (14): 2276-2284
74. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006 Nov 15; 60 (10): 1111-1120
75. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001 Nov; 108 (5): E83
76. Forero DA, Arboleda GH, Vasuez R, et al. Candidate genes involved in neural plasticity and the risk for attention-deficit hyperactivity disorder: a meta-analysis of 8 common variants. J Psychiatry Neurosci 2009; 34 (5): 361-366
77. Dlugos A, Freitag C, Hohoff C, et al. Norepinephrine transporter gene variation modulates acute response to D-amphetamine. Biol Psychiatry 2007 Jun 1; 61 (11): 1296-1305
78. Schiavo G, Stenbeck G, Rothman JE, et al. Binding of the synaptic vesicle v-SNARE, synaptotagmin, to the plasma membrane t-SNARE, SNAP-25, can explain docked vesicles at neurotoxin-treated synapses. Proc Natl Acad Sci USA 1997 Feb 4; 94 (3): 997-1001
79. Barr CL, Feng Y, Wigg K, et al. Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. Mol Psychiatry 2000 Jul; 5 (4): 405-409 (Pubitemid 30455954)
80. Brophy K, Hawi Z, Kirley A, et al. Synaptosomal-associated protein 25 (SNAP-25) and attention deficit hyperactivity disorder (ADHD): evidence of linkage and association in the Irish population. Mol Psychiatry 2002; 7 (8): 913-917
81. Kustanovich V, Merriman B, McGough J, et al. Biased paternal transmission of SNAP-25 risk alleles in attention-deficit hyperactivity disorder. Mol Psychiatry 2003 Mar; 8 (3): 309-315
82. Mill J, Curran S, Kent L, et al. Association study of a SNAP-25 microsatellite and attention deficit hyper-activity disorder. Am J Med Genet 2002 Apr 8; 114 (3): 269-271
83. Wilson MC. Coloboma mouse mutant as an animal model of hyperkinesis and attention deficit hyperactivity disorder. Neurosci Biobehav Rev 2000 Jan; 24 (1): 51-57
84. Polanczyk G, Zeni C, Genro JP, et al. Attention-deficit/ hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics 2005 Apr; 6 (3): 225-234
85. Sun Z, Murry DJ, Sanghani SP, et al. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A 1. J Pharmacol Exper Ther 2004 Aug; 310 (2): 469-476
86. Zhu HJ, Patrick KS, Yuan HJ, et al. Two CES1 gene mu-tations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet 2008 Jun; 82 (6): 1241-1248
87. Dring LG, Smith RL, Williams RT. The metabolic fate of amphetamine in man and other species. Biochemical J 1970 Feb; 116 (3): 425-435
88. Markowitz JS, Patrick KS. Pharmacokinetic and pharma-codynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 2001; 40 (10): 753-772
89. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-296
90. McGough JJ, Biederman J, Greenhill LL, et al. Pharma-cokinetics of SLI381 (ADDERALL XR) an extended release formulation of Adderall. J Am Acad Child Adolesc Psychiatry 2003; 42 (6): 684-691
91. Wandel C, Witte JS, Hall JM, et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5-promoter region polymorphism. Clin Pharmacol Ther 2000 Jul; 68 (1): 82-91
92. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007 Feb; 46 (2): 242-251
93. Waldman ID, Gizer IR. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev 2006 Aug; 26 (4): 396-432
94. Friedel S, Saar K, Sauer S, et al. Association and linkage of allelic variants of the dopamine transporter gene in ADHD. Mol Psychiatry 2007 Oct; 12 (10): 923-933
95. Van der Meulen EM, Bakker SC, Pauls DL, et al. A genome-wide quantitative trait locus analysis on methylphenidate response rate in Dutch sibpairs with attention-deficit/ hyperactivity disorder. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions; 2004 Aug 22-26; Berlin
96. Mick E, Neale B, Middleton FA, et al. Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsych Genet 2008 Sep; 147B: 7412-7414
97. Pelham WE, Millich R. Individual differences in response to Ritalin in class work and social behavior. In: Greenhill L, Osman B, editors. Ritalin: theory and patient management. New York: Mary Ann Liebert, 1991
98. Brody AL, Mandelkern MA, Olmstead RE, et al. Gene variants of brain dopamine pathways and smoking-induced dopamine release in the ventral caudate/nucleus accumbens. Arch Gen Psychiatry 2006 Jul; 63 (7): 808-816
99. Li S, Kim KY, Kim JH, et al. Chronic nicotine and smok-ing treatment increases dopamine transporter mRNA expression in the rat midbrain. Neurosci Lett 2004 Jun 3; 363 (1): 29-32
100. Gerasimov MR, Franceschi M, Volkow ND, et al. Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 2000 Dec 15; 38 (4): 432-437
101. Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genom Human Genet 2006; 7: 223-245
102. ADHD Molecular Genetics Network Annual International Meeting; 2006 Oct 8-10; Brussels
103. ADHD Molecular Genetics Network Annual International Meeting; 2008 Dec 5-7; Sanibel Island (FL)
104. Pliszka SR, Crismon ML, Hughes CW, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Jun; 45 (6): 642-657
105. McGough JJ, Biederman J, Wigal SB, et al. Long-term tolerability and effectiveness of once-daily mixed amphetamine salts (Adderall XR) in children with ADHD. J Am Acad Child Adolesc Psychiatry 2005 Jun; 44 (6): 530-538 (Pubitemid 40720952)
106. Wilens T, Pelham W, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2003 Apr; 42 (4): 424-433
107. Wigal T, Greenhill L, Chuang S, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry 2006 Nov; 45 (11): 1294-1303 (Pubitemid 44665446)